Background: Wilson’s disease (WD) is a treatable autosomal recessive metabolic disorder which could lead to protean hepatic or neurologic manifestations. WD could mimic many neurologic disorders and is often diagnosed with a long delay. This study describes central nervous system manifestations of a group of Iranian patients with neurologic WD. Methods: Data from case records of patients with neurologic WD presenting at a referral university hospital and a private clinic in Tehran from 1984 to 2004 were analyzed. Results: Fifty patients from 44 unrelated families with WD were identified, whose mean duration of follow-up was 51.8 (±58.5) months. The median age of onset of neurologic symptoms in 37 patients with primary neurologic or simultaneous hepatic-neurologic presentation was 16 (10–38) years, whereas in 13 patients with prior hepatic damage, this was 18.5 (11–34) years. The 6 most common manifestations were dysarthria (80%), drooling (48%), tremor in limbs (44%), abnormal gait (44%), psychiatric and/or sleep symptoms (44%), and dystonia in limbs (42%). Conclusion: Neurologic WD has heterogeneous manifestations and should be considered in young patients presenting with dysarthria, drooling, any kind of movement disorders or psychiatric symptoms.

1.
Walshe JM, Yealland M: Wilson’s disease: the problem of delayed diagnosis. J Neurol Neurosurg Psychiatry 1992;55:692–696.
2.
Prashanth LK, Taly AB, Sinha S, Arunodaya GR, Swamy HS: Wilson’s disease: diagnostic errors and clinical implications. J Neurol Neurosurg Psychiatry 2004;75:907–909.
3.
Roberts EA, Schilsky ML: A practice guideline on Wilson disease. Hepatology 2003;37:1475–1492.
4.
Pellecchia MT, Criscuolo C, Longo K, Campanella G, Filla A, Barone P: Clinical presentation and treatment of Wilson’s disease: a single-centre experience. Eur Neurol 2003;50:48–52.
5.
Kashani AA: Ocular manifestations of Wilson’s disease in Iran. Trans Ophthalmol Soc UK 1977;97:18–19.
6.
Oder W, Grimm G, Kollegger H, Ferenci P, Schneider B, Deecke L: Neurological and neuropsychiatric spectrum of Wilson’s disease: a prospective study of 45 cases. J Neurol 1991;238:281–287.
7.
Demirkiran M, Jankovic J, Lewis RA, Cox DW: Neurologic presentation of Wilson disease without Kayser-Fleischer rings. Neurology 1996;46:1040–1043.
8.
Ansari R, Malekzadeh R, Ebrahimi-Daryani N, Mirdamadi MJ, Sohrabi MR, Mortazavi-Tabatabaei SA: A prospective study of the clinical and paraclinical features of Wilson’s disease in Iran. Arch Iran Med 2000;3:119–123.
9.
Oder W, Prayer L, Grimm G, Spatt J, Ferenci P, Kollegger H, Schneider B, Gangl A, Deecke L: Wilson’s disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology 1993;43:120–124.
10.
Hoogenraad TU: Wilson’s Disease. Amsterdam, Intermed Medical Publishers, 2001, pp 71–108.
11.
Berry WR, Darley FL, Aronson AE: Dysarthria in Wilson’s disease. J Speech Hear Res 1974;17:169–183.
12.
Liao KK, Wang SJ, Kwan SY, Kong KW, Wu ZA: Tongue dyskinesia as an early manifestation of Wilson disease. Brain Dev 1991;13:451–453.
13.
Kumar TS, Moses PD: Isolated tongue involvement: an unusual presentation of Wilson’s disease. J Postgrad Med 2005;51:337.
14.
Alm PA: Stuttering and the basal ganglia circuits: a critical review of possible relations. J Commun Disord 2004;37:325–369.
15.
Benke T, Hohenstein C, Poewe W, Butterworth B: Repetitive speech phenomena in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000;69:319–324.
16.
Khan A, Khattak A, Sherin A, Khalil MA: Neurological manifestations of Wilson’s disease. J Postgrad Med Inst 2003;17:14–19.
17.
Nicholl DJ, Ferenci P, Polli C, Burdon MB, Pall HS: Wilson’s disease presenting in a family with an apparent dominant history of tremor. J Neurol Neurosurg Psychiatry 2001;70:514–516.
18.
Carlson MD, Al-Mateen M, Brewer GJ: Atypical childhood Wilson’s disease. Pediatr Neurol 2004;30:57–60.
19.
BerardelliA, Inghilleri M, Priori A, Thompson PD, Fabri S, Fieschi C, Manfredi M: Involvement of corticospinal tract in Wilson’s disease: a study of three cases with transcranial stimulation. Mov Disord 1990;5:334–337.
20.
Dening TR, Berrios GE, Walshe JM: Wilson’s disease and epilepsy. Brain 1988;111:1139–1155.
21.
Kumar S: Wilson’s disease presenting as status epilepticus. Indian Pediatr 2005;42:492–493.
22.
Portala K, Westermark K, Ekselius L, Broman JE: Sleep in patients with treated Wilson’s disease: a questionnaire study. Nord J Psychiatry 2002;56:291–297.
23.
Firneisz G, Szalay F, Halasz P, Komoly S: Hypersomnia in Wilson’s disease: an unusual symptom in an unusual case. Acta Neurol Scand 2000;101:286–288.
24.
Gennaro GD, Autret A, Mascia A, Onorati P, Sebastianoa F, Quarato PP: Night terrors associated with thalamic lesion. Clin Neurophysiol 2004;115:2489–2492.
25.
Dening TR, Berrios GE: Wilson’s disease: psychiatric symptoms in 195 cases. Arch Gen Psychiatry 1989;46:1126–1134.
26.
Canelas HM, Carvalho N, Scaff M, Vitule A, Barbosa ER, Azevedo EM: Osteoarthropathy of hepatolenticular degeneration. Acta Neurol Scand 1978;57:481–487.
27.
Golding DN, Walshe JM: Arthropathy of Wilson’s disease: study of clinical and radiological features in 32 patients. Ann Rheum Dis 1977;36:99–111.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.